<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303325</url>
  </required_header>
  <id_info>
    <org_study_id>20200225</org_study_id>
    <nct_id>NCT04303325</nct_id>
  </id_info>
  <brief_title>Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)</brief_title>
  <acronym>ESPOD-BI</acronym>
  <official_title>Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, controlled (randomized, parallel group, concealed
      allocation), double-blinded trial. All depression patients undergoing breast cancer operation
      will be randomized 1:1 to the treatment intervention with general anesthesia as an adjunct to
      esketamine or saline. The objective of the trial is to evaluate the postoperative
      depression、gut microbiota、bispectral index data of patients undergoing breast cancer
      operation with esketamine or saline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For female patients, breast cancer patients have a high risk of developing depression, and
      approximately 20%-45% of breast cancer patients suffer from postoperative depression.
      Esketamine is an anesthetic in analgesia, and has presently become more and more popular for
      treating anti-depression, particularly for resistant depression.

      This study is a prospective, randomized, controlled (randomized, parallel group, concealed
      allocation), double-blinded trial. All depression patients undergoing breast cancer operation
      will be randomized 1:1 to the treatment intervention with general anesthesia as an adjunct to
      esketamine or saline. The objective of the trial is to evaluate the postoperative
      depression、gut microbiota、bispectral index data of patients undergoing breast cancer
      operation with esketamine or saline
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 6, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-asberg Depression Rating Scale score</measure>
    <time_frame>from baseline to postoperative 24 hours</time_frame>
    <description>Changes of Montgomery-asberg Depression Rating Scale score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bispectral index</measure>
    <time_frame>from 8pm to 6am on the first postoperative night</time_frame>
    <description>Changes of bispectral index data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>from baseline to postoperative 72 hours</time_frame>
    <description>changs of gut microbiota</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine 0.2mg/kg.</description>
    <arm_group_label>Esketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least18 years and pre-menopausal;

          -  scheduled to undergo elective breast cancer operation;

          -  American Society of Anaesthesiologists (ASA) risk classification I-II.

          -  Montgomery-asberg Depression Rating Scale (MADRS) score ≥22

        Exclusion Criteria:

          -  Cognitive difficulties

          -  Partial or complete gastrectomy

          -  Previous esophageal surgery

          -  Inability to conform to the study's requirements

          -  Ongoing participation or participation in another study &lt;1 month ago
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Wen-fei Tan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>sleep deprivation</keyword>
  <keyword>gut microbiota</keyword>
  <keyword>bispectral index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

